Significant shareholders:
| Shareholder/Beneficial Owner | Shares | % ISC |
|---|---|---|
| Invesco | 142,161,455 | 17.72 |
| T Rowe Price Global Investments | 83,545,143 | 10.41 |
| Canaccord Genuity Wealth Management | 64,715,685 | 8.07 |
| Hargreaves Lansdown, stockbrokers | 57,631,971 | 7.18 |
| Interactive Investor | 40,346,763 | 5.03 |
| Dr Andrew W Nelson* | 36,140,417 | 4.54 |
| M&G Investments | 27,742,549 | 3.46 |
| AXA Framlington Investment Managers | 25,836,499 | 3.22 |
| Lombard Odier Investment Managers | 24,681,480 | 3.08 |
as at 30 September 2021
Quoted: AIM (London Stock Exchange)
Other Exchanges / Trading Platforms: The Company is not listed on any other exchanges or trading platforms.
Number of securities in issue: 802,267,824 Ordinary shares.
Shares not in public hands: Insofar as the Company is aware, the percentage of securities that is not in public hands is 33.8%, these being held by directors, their families and significant shareholders.
Own shares held in treasury: The Company holds 4,115 Ordinary Shares in treasury.
Details on any restrictions on the transfer of securities: There are no restrictions on the transfer of securities.
Applicable code(s): The Company is subject to the UK City Code on Takeovers and Mergers. The Code is administered by The Panel and Takeovers in Mergers.
* Per the Company’s RNS announcement of 11 May 2020, 12,121,711 Ordinary Shares of Dr Nelson’s total beneficial interest are subject to a Sale and Repurchase Agreement with Equities First Holdings.